Boston Scientific lifts FY25 outlook amid continued cardiovascular boom
Boston Scientific has lifted its fiscal year 2025 (FY25) profit outlook to between $3.02 and $3.04 per share amid continued strong performance in its third quarter (Q3), largely driven by growth in its cardiovascular business.
The company now expects profits of $3.02 and $3.04 per share for FY25, up from $2.95 to $2.99 previously.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Following the Q3 result’s announcement, Boston’s share price on the New York Stock Exchange (NYSE) rose by more than 4% to around $104 per share, up from $103.10 at market open on 22 October. Boston has a market cap of around $153bn.
With continued uptake of its Farapulse pulsed-field ablation (PFA) system, the FY25 uplift reflects Boston’s second full year profit uplift in 2025, having previously raised its profit expectations for 2025 from $2.87 to $2.94 per share following Q2 results.
Boston’s financials revealed total sales of more than $5bn in Q3 2025, reflecting a 20.4% rise versus $4.2bn in Q3 2024.
Much of the total revenue was attributable to growth in Boston’s cardiovascular portfolio, with revenue exceeding $3.3bn, indicative of a 22.4% rise from $2.7bn in Q3 2024.
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataDuring a post-earnings conference call, Boston’s CEO Mike Mahoney shared that 500,000 patients to date have been treated with Farapulse, with “consistent and reproducible real-world results”.
He commented: “Continued strong double-digit growth in Farapulse is supported by ramping adoption of our OPAL HDx Mapping System, with one in three Farapulse accounts now utilising our integrated FARAWAVE NAV PFA catheter and OPAL device.”
Rival medtech company Medtronic recently lifted its FY26 profit outlook to between $5.60 and $5.66 per share after the cardiac rhythm and heart failure segment within its cardiovascular portfolio climbed to around $1.7bn in Q1 2026, denoting an 11.5% rise on $1.53bn in Q1 of FY26.
The uplift for Medtronic reflects the ongoing adoption of its Affera mapping and ablation system featuring the Sphere-9 Catheter, and PulseSelect PFA for the treatment of atrial fibrillation (AFib). Competing for market share against Boston’s Farapulse PFA, PulseSelect gained US Food and Drug Administration (FDA) clearance in December 2023, ahead of Farapulse’s clearance from the agency in January 2024.
Elsewhere across the business, revenue in Boston’s MedSurg portfolio swelled to around $1.7bn, denoting a 16.4% rise on Q3 2024, with Boston’s urology segment rising by 28.1% to $682m. The neuromodulation segment within Boston’s MedSurg portfolio grew by 9.1% to $293m.
In Boston’s earnings call, Mahoney highlighted that the company expects the recent $533m acquisition of Nalu Medical to complement the company’s commercial strength within the interventional pain segment.
Designed to address chronic pain in regions such as the shoulder and lower back via peripheral nerve stimulation (PNS), Nalu’s neurostimulation system adds to Boston’s existing pain management therapies in spinal cord stimulation, basivertebral nerve ablation, and radiofrequency ablation.
Sign up for our daily news round-up!
Give your business an edge with our leading industry insights.
Medical Device Network Excellence Awards - The Benefits of Entering
Gain the recognition you deserve! The Medical Device Network Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving medical devices advancements. Don’t miss your chance to stand out—submit your entry today!
Nominate NowContent Original Link:
" target="_blank">
